CV-PP-10 · standards v1.4.1
Dual, and the more serious of the two is FDA: a name borrowing a drug's identity is evidence of intended use under s.201(g). Amazon is why it gets fixed this week.
Found on 57 of the 2,243 best-selling listings we have ruled, 80 times in total. That is 57 live product pages carrying this wording today.
Amazon Seller Central, Dietary Supplements policy
“prohibited claims in listing content including title, bullets, description and search terms”
Source checked 2026-08-18.
FDCA s.201(g)(1)(B), 21 U.S.C. 321(g)(1)(B)
“definition of 'drug': articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease”
Source checked 2026-08-18.
Stripe Prohibited and Restricted Businesses
“Prohibited Businesses: nutraceuticals and pseudo-pharmaceuticals; unfair, deceptive or abusive acts or practices”
Source checked 2026-09-13.
An interpretation. We applied a published legal test to the published copy and reached a conclusion. Reasonable reviewers applying the same test can disagree at the margin; this is our reviewer's professional opinion, and the test is cited so you can check the reasoning.
Claims Verified, standard CV-PP-10 "Prescription drug name or drug-equivalence claim", standards v1.4.1, retrieved 06 November 2026, https://claimsverified.org/standards/CV-PP-10/
Or put it in your own policy
Marketing copy must not use "Prescription drug name or drug-equivalence claim" or equivalent wording. See Claims Verified standard CV-PP-10 (standards v1.4.1): https://claimsverified.org/standards/CV-PP-10/
Cite it freely with attribution and the version. The whole register is machine-readable at /standards/registry.json. Rulings are our published professional opinion, not legal advice.
All 109 standards and the 109 in force · Check a listing against them free
The independent standard for supplement and telehealth claims. Our AI rules a brand’s public supplement claims against 109 published standards. Each failing line is rewritten to the rules. A licensed pharmacist signs every Claims Review Report.